BioLineRx Enters into “At-The-Market” Offering Agreement with Stifel, Nicolaus & Company

  BioLineRx Enters into “At-The-Market” Offering Agreement with Stifel,
  Nicolaus & Company

Business Wire

JERUSALEM -- May 17, 2013

BioLineRx Ltd. (NASDAQ: BLRX)(TASE: BLRX), a biopharmaceutical development
company, announced today that it has entered into an at-the-market (ATM) sales
agency agreement with Stifel. Pursuant to this agreement, the Company may from
time to time, in its discretion, sell up to a maximum of $20,000,000 of the
Company’s American Depositary Shares (ADSs). Each ADS represents ten Ordinary
Shares of the Company.

The ATM program does not constitute an immediate sale of the Company’s ADSs.
The program permits the Company to raise capital at the times and in amounts
deemed suitable by management.The Company is not required to sell any ADSs at
any time. The Company intends to use net proceeds from the ATM facility, if
any, to fund clinical trials and for working capital and general corporate
purposes.

“We believe that an ATM program is an efficient approach to raise capital, if
necessary, on an as needed basis. It is designed to enable operational
flexibility,” said Dr. Kinneret Savitsky, Chief Executive Officer of
BioLineRx.

ATM sales, if any, will be made pursuant to a prospectus supplement, dated May
17, 2013, to the Company’s prospectus dated August 14, 2012, filed as part of
its effective shelf registration statement on Form F-3 (File No. 333-182997)
previously filed with, and declared effective by, the Securities and Exchange
Commission (SEC). Before you invest, you should read the base prospectus in
such shelf registration statement, the prospectus supplement, and other
documents the Company has filed with the SEC, for more complete information
about the Company and this offering. The offering may be made only by means of
a prospectus supplement and the accompanying prospectus, copies of which may
be obtained for free by visiting EDGAR on the SEC website at www.sec.gov or by
sending a request to the offices of the Company, P.O. Box 45158, 19 Hartum
Street, Jerusalem 91450, Israel, or by telephone at +972-2-548-9100, or email:
info@BioLineRx.com.

This press release shall not constitute an offer to sell, or the solicitation
of an offer to buy, any of the ADSs or Ordinary Shares of the Company, nor
shall there be any sale of these ADSs or Ordinary Shares of the Company, in
any state or other jurisdiction in which such offer, solicitation or sale
would be unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction.

About BioLineRx

BioLineRx is a publicly-traded biopharmaceutical development company.
BioLineRx is dedicated to building a portfolio of products for unmet medical
needs or with advantages over currently available therapies. BioLineRx’s
current portfolio consists of seven clinical stage candidates: BL-1040, for
prevention of pathological cardiac remodeling following a myocardial
infarction, which has been out-licensed to Ikaria Inc., is currently
undergoing a pivotal CE-Mark registration trial; BL-5010 for non-surgical
removal of skin lesions has completed a Phase 1/2 study; BL-7040 for treating
inflammatory bowel disease (IBD) has completed a Phase 2a trial; BL-8040 for
treating acute myeloid leukemia (AML) and other hematological cancers will
shortly commence a Phase 2 study; BL-1021 for neuropathic pain is in Phase 1
development; BL-8020 for hepatitis C (HCV) has commenced a Phase 1/2 study;
and BL-1020 for schizophrenia. In addition, BioLineRx has five products in
various pre-clinical development stages for a variety of indications,
including central nervous system diseases, infectious diseases, cardiovascular
and autoimmune diseases.

BioLineRx’s business model is based on acquiring molecules mainly from
biotechnological incubators and academic institutions. The Company performs
feasibility assessment studies and development through pre-clinical and
clinical stages, with partial funding from the Israeli Government’s Office of
the Chief Scientist (OCS). The final stage includes partnering with medium and
large pharmaceutical companies for advanced clinical development (Phase 3) and
commercialization. For more information on BioLineRx, please visit
www.biolinerx.com, the content of which does not form a part of this press
release.

Various statements in this release concerning BioLineRx’s future expectations
constitute “forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements include words such
as “may,” “expects,” “anticipates,” “believes,” and “intends,” and describe
opinions about future events. These forward-looking statements involve known
and unknown risks and uncertainties that may cause the actual results,
performance or achievements of BioLineRx to be materially different from any
future results, performance or achievements expressed or implied by such
forward-looking statements. Some of these risks are: changes in relationships
with collaborators; the impact of competitive products and technological
changes; risks relating to the development of new products; and the ability to
implement technological improvements. These and other factors are more fully
discussed in the “Risk Factors” section of BioLineRx’s most recent annual
report on Form 20-F filed with the Securities and Exchange Commission on March
12, 2013. In addition, any forward-looking statements represent BioLineRx’s
views only as of the date of this release and should not be relied upon as
representing its views as of any subsequent date. BioLineRx does not assume
any obligation to update any forward-looking statements unless required by
law.

Contact:

KCSA Strategic Communications
Garth Russell, 1 212-896-1250
grussell@kcsa.com
or
Todd Fromer, 1 212-896-1215
tfromer@kcsa.com
or
Tsipi Haitovsky, Public Relations
+972-52-598-9892
tsipih@netvision.net.il
 
Press spacebar to pause and continue. Press esc to stop.